 Well, I can tell you, based on internal FDA memos and transcripts, Janet Woodcock and Peter Marks, who's currently the director of the Center for Biologics and Evaluations Research, have gone on record in stating that they need to lower the standards for safety and efficacy in the name of innovation to reduce